Get started
Keyword

EO9

Description: EO9 is an indoloquinone anticancer drug that acts as a bioreductive alkylating agent and has been investigated in preclinical and clinical oncology.
OpenAlex ID: keywords/eo9
Reductase Enzyme Expression Across the National Cancer Institute Tumor Cell Line Panel: Correlation With Sensitivity to Mitomycin C and EO9
1996 · S. A. Fitzsimmons, P. Workman, et al. · JNCI Journal of the National Cancer Institute · 232
PDF
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
2013 · Christopher P. Guise, Alexandra M. Mowday, et al. · 癌症：英文版 · 170
PDF
The experimental development of bioreductive drugs and their role in cancer therapy
1993 · P. Workman, I. J. Stratford · Cancer and Metastasis Reviews · 136
Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways
2014 · S J Allison, J R P Knight, et al. · Oncogenesis · 135
PDF
Effect of Hyperthermia on the Cytotoxicity of 4 Chemotherapeutic Agents Currently Used for the Treatment of Transitional Cell Carcinoma of the Bladder: an in Vitro Study
2005 · ANTOINE G. van der HEIJDEN, GERALD VERHAEGH, et al. · The Journal of Urology · 116
EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models
1993 · H.R. Hendriks, P.E. Pizao, et al. · European Journal of Cancer · 104
Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
1995 · H D Beall, A M Murphy, et al. · Molecular Pharmacology · 96
Structure-Based Development of Anticancer Drugs
2001 · Margarita Faig, Mario A. Bianchet, et al. · Structure · 83
PDF
Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies
2007 · Andrew Evans, Victoria Bates, et al. · Cancer Chemotherapy and Pharmacology · 82
Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours
1998 · RM Phillips, PM Loadman, et al. · British Journal of Cancer · 81
Induction of DT-diaphorase in cancer chemoprevention and chemotherapy.
1997 · A Begleiter, M K Leith, et al. · PubMed · 81
Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia
1994 · N. Robertson, A. Haigh, et al. · European Journal of Cancer · 76
The sensitivity of human tumour cells to quinone bioreductive drugs: What role for DT-diaphorase?
1992 · N. Robertson, I.J. Stratford, et al. · Biochemical Pharmacology · 76
Aziridinyl Quinone Antitumor Agents Based on Indoles and Cyclopent[b]indoles: Structure−Activity Relationships for Cytotoxicity and Antitumor Activity
2001 · Edward B. Skibo, Chengguo Xing, et al. · Journal of Medicinal Chemistry · 74
NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs
2006 · Claudia M. Celli, Namphuong Tran, et al. · Biochemical Pharmacology · 69
Clinical applications of quinone-containing alkylating agents
2000 · Asher Begleiter · Frontiers in bioscience · 68
PDF
DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?
1995 · E Smitskamp-Wilms, G Giaccone, et al. · British Journal of Cancer · 62
PDF
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group
1996 · L.Y. Dirix, F. Tonnesen, et al. · European Journal of Cancer · 61
Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones
2000 · Robert, H. J. Hargreaves · Frontiers in bioscience · 60
PDF
Bioreductive Activation of a Series of Indolequinones by Human DT-Diaphorase: Structure−Activity Relationships
1999 · Roger M. Phillips, Matthew A. Naylor, et al. · Journal of Medicinal Chemistry · 59
Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes.
1995 · S Chen, R Knox, et al. · Molecular Pharmacology · 56
Relative importance of DT-diaphorase and hypoxia in the bioactivation of e09 by human lung tumor cell lines
1994 · Jane A. Plumb, Martijn Gerritsen, et al. · International Journal of Radiation Oncology*Biology*Physics · 55
Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs
2004 · Roger M. Phillips, Mohammed Jaffar, et al. · Biochemical Pharmacology · 54
A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9
2001 · G A Choudry, P A Hamilton Stewart, et al. · British Journal of Cancer · 52
PDF
Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
1996 · D L Gustafson, H D Beall, et al. · Molecular Pharmacology · 52
Works count: 108
Citation count: 3,631
Year
Topic
Type